Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied. A clinically significant effect on clarithromycin is unlikely as it is mainly metabolized by CYP3A4 and clarithromycin is unlikely to affect emtricitabine concentrations. However, clarithromycin is an inhibitor of P-gp and could potentially increase the absorption of tenofovir-DF, thereby increasing the systemic concentration of tenofovir. Monitoring of tenofovir-associated adverse reactions, including frequent renal monitoring, is recommended.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking